Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00048295
Recruitment Status : Unknown
Verified April 2004 by Ionis Pharmaceuticals, Inc.. Recruitment status was: Active, not recruiting
ISIS 2302 is an antisense oligonucleotide drug that reduces the production of a specific protein called intercellular adhesion molecule (ICAM-1), a substance that plays a significant role in the increase of inflammation. People with Crohn's disease have been shown to over-produce ICAM-1 in their gut tissues. Alicaforsen works by blocking ICAM-1 messenger RNA, the "instruction" molecule that is required for the production of ICAM-1 protein. This trial will examine effects of alicaforsen delivered by 2-hour intravenous infusion over a four-week period, compared to a placebo. Patients may remain on stable background 5-ASA, antibiotic, or immunosuppressive drugs, and prednisone (or equivalent) at </= 30 mg per day.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
12 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Age >/= 12 years
Weight >/= 36 kg
CDAI score of 220 - 400
Documentation of Crohn's disease activity by endoscopy, biopsy or imaging in the last 2 years
No TNF-α inhibitor treatment for three months prior to first study drug infusion
Known severe, fixed, symptomatic stenosis of the small or large intestine with significant dilation
Extensive external fistulization (> 3 external fistulae which are expressible with gentle compression); colostomy or ileostomy
Active infection, including infectious colitis, or infection with HIV, Hepatitis B or Hepatitis C
Malignancy within 3 years or poorly controlled medical illness
Requires intravenous heparin therapy or with a history of a bleeding problem